3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
US8969583B2 · kind B2 · utility
0Cited by
8References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 27, 2012 |
| Grant date | Mar 3, 2015 |
| Priority date | — |
| Expiry date | Dec 27, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D295/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, n, X1, X2, L1, and L2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.